CN114040921A - 用于不同类型癌症免疫治疗的非经典来源的肽和肽组合 - Google Patents

用于不同类型癌症免疫治疗的非经典来源的肽和肽组合 Download PDF

Info

Publication number
CN114040921A
CN114040921A CN201980013690.5A CN201980013690A CN114040921A CN 114040921 A CN114040921 A CN 114040921A CN 201980013690 A CN201980013690 A CN 201980013690A CN 114040921 A CN114040921 A CN 114040921A
Authority
CN
China
Prior art keywords
peptide
cancer
cells
peptides
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980013690.5A
Other languages
English (en)
Chinese (zh)
Inventor
H·舒斯特
F·霍夫加德
J·弗里奇
O·朔尔
T·温申克
D·瓦勒夫斯基
C·C·邹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to CN202011611064.7A priority Critical patent/CN112920257A/zh
Priority to CN202411279163.8A priority patent/CN119306794A/zh
Publication of CN114040921A publication Critical patent/CN114040921A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001118—Receptors for colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980013690.5A 2018-02-21 2019-02-08 用于不同类型癌症免疫治疗的非经典来源的肽和肽组合 Pending CN114040921A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202011611064.7A CN112920257A (zh) 2018-02-21 2019-02-08 用于不同类型癌症免疫治疗的非经典来源的肽和肽组合
CN202411279163.8A CN119306794A (zh) 2018-02-21 2019-02-08 用于不同类型癌症免疫治疗的非经典来源的肽和肽组合

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862633325P 2018-02-21 2018-02-21
DE102018103944 2018-02-21
US62/633,325 2018-02-21
DE102018103944.1 2018-02-21
DE102018107224.4 2018-03-27
DE102018107224.4A DE102018107224A1 (de) 2018-02-21 2018-03-27 Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
PCT/EP2019/053168 WO2019162110A1 (en) 2018-02-21 2019-02-08 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202011611064.7A Division CN112920257A (zh) 2018-02-21 2019-02-08 用于不同类型癌症免疫治疗的非经典来源的肽和肽组合
CN202411279163.8A Division CN119306794A (zh) 2018-02-21 2019-02-08 用于不同类型癌症免疫治疗的非经典来源的肽和肽组合

Publications (1)

Publication Number Publication Date
CN114040921A true CN114040921A (zh) 2022-02-11

Family

ID=67482070

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980013690.5A Pending CN114040921A (zh) 2018-02-21 2019-02-08 用于不同类型癌症免疫治疗的非经典来源的肽和肽组合

Country Status (22)

Country Link
US (79) US10993962B2 (enExample)
EP (2) EP3755708A1 (enExample)
JP (4) JP7536642B2 (enExample)
KR (2) KR20200123134A (enExample)
CN (1) CN114040921A (enExample)
AU (5) AU2019225879B2 (enExample)
BR (2) BR122020014377A8 (enExample)
CA (1) CA3086916A1 (enExample)
CL (4) CL2020002123A1 (enExample)
CO (1) CO2020009869A2 (enExample)
CR (1) CR20200365A (enExample)
DE (1) DE102018107224A1 (enExample)
EA (2) EA202091754A1 (enExample)
IL (2) IL276845A (enExample)
MA (1) MA51890A (enExample)
MX (2) MX2020007767A (enExample)
MY (1) MY200985A (enExample)
PE (2) PE20211300A1 (enExample)
PH (1) PH12020551295A1 (enExample)
SG (2) SG11202006630RA (enExample)
TW (3) TWI837747B (enExample)
WO (1) WO2019162110A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
ES2991645T3 (es) 2019-06-06 2024-12-04 Immatics Biotechnologies Gmbh Clasificación con contraselección mediante péptidos de secuencia similar
JP2022545541A (ja) * 2019-08-28 2022-10-27 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
US12250668B2 (en) 2020-10-16 2025-03-11 Apple Inc. System and method for fast beam tracking in a high frequency wireless communication system
JP2024502034A (ja) 2020-12-31 2024-01-17 イマティクス ユーエス，アイエヌシー． Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
MX2023012899A (es) 2021-05-05 2023-11-08 Immatics Biotechnologies Gmbh Polipeptidos de union a antigeno bma031 mejorados.
CN118234745A (zh) * 2021-09-17 2024-06-21 蒙特利尔大学 用于结直肠癌的新型肿瘤特异性抗原及其用途
JP2025503323A (ja) 2022-01-25 2025-01-30 イーアールブイイミューン Ｈｅｒｖ由来エピトープを同定するための新規方法
AU2023262596A1 (en) 2022-04-28 2024-12-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514834A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2025211983A1 (ru) * 2024-04-05 2025-10-09 Общество с ограниченной ответственностью "Альбоген" Пептиды с противоопухолевой активностью

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IE53176B1 (en) 1978-12-22 1988-08-17 Biogen Nv Recombinant dna molecules and their method of production
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
WO1994029347A1 (en) 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Antibody fragments in therapy
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
WO1997026328A1 (en) 1996-01-17 1997-07-24 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US5759812A (en) * 1996-11-15 1998-06-02 Incyte Pharmaceuticals, Inc. Human selenium-binding protein
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU6027399A (en) 1998-09-04 2000-03-27 Ludwig Institute For Cancer Research An antigenic peptide encoded by an alternative open reading frame of human macrophage colony-stimulating factor
EP1001022A1 (en) 1998-10-16 2000-05-17 Boehringer Ingelheim International GmbH CAMEL, an alternative translation product of the tumour antigen LAGE-1
US7504490B1 (en) 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
US6881564B1 (en) 1999-09-10 2005-04-19 The University Of Sydney Dipeptidyl peptidases
JP2004503213A (ja) 2000-03-27 2004-02-05 テクニオン　リサーチ　アンド　ディベロップメント　ファウンデーション　リミテッド １本鎖クラスｉ主要組織適合性複合体、それをコードする構築物およびそれを生成する方法
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
AU2001275246B2 (en) 2000-06-05 2006-06-29 Altor Bioscience Corporation T cell receptor fusions and conjugates and methods of use thereof
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
NZ539226A (en) 2002-11-09 2008-09-26 Medigene Ltd T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
DE102005041616B4 (de) * 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
ES2341802T3 (es) 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
US8097256B2 (en) 2006-09-28 2012-01-17 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
EP2113253B1 (en) 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
NO2119726T3 (enExample) 2008-05-14 2015-05-23
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
CA2816225A1 (en) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
WO2014071978A1 (en) 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Nucleic acids encoding chimeric polypeptides for library screening
WO2014096399A1 (en) 2012-12-21 2014-06-26 Technische Universität Dresden Manipulation of hairy and split 3 (hes3) and its regulators/mediators as a new anti-cancer strategy
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI775117B (zh) 2013-08-05 2022-08-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二）
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
WO2016172722A1 (en) * 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201520579D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
EA201892333A1 (ru) 2016-04-21 2019-03-29 Имматикс Байотекнолоджиз Гмбх Иммунотерапия меланомы и других видов рака
TWI796299B (zh) * 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
US12221465B2 (en) * 2017-09-06 2025-02-11 California Institute Of Technology Signaling and antigen-presenting bifunctional receptors (SABR)
FR3070845B1 (fr) 2017-09-13 2021-07-30 Oreal Outil de mesure d'au moins une propriete d'une surface corporelle et procede de mesure associe
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof

Also Published As

Publication number Publication date
US11040069B2 (en) 2021-06-22
AU2022202522B2 (en) 2023-12-21
TWI776160B (zh) 2022-09-01
US11951132B2 (en) 2024-04-09
US20190255113A1 (en) 2019-08-22
IL276845A (en) 2020-10-29
US10813953B2 (en) 2020-10-27
AU2020204568A1 (en) 2020-07-30
DE102018107224A1 (de) 2019-08-22
US11013768B2 (en) 2021-05-25
US20210137985A1 (en) 2021-05-13
US20210330708A1 (en) 2021-10-28
US20200360433A1 (en) 2020-11-19
US10780123B2 (en) 2020-09-22
US10695376B2 (en) 2020-06-30
US20200323916A1 (en) 2020-10-15
US10905720B2 (en) 2021-02-02
US20210401892A1 (en) 2021-12-30
US20200306311A1 (en) 2020-10-01
US10993964B2 (en) 2021-05-04
US20230241115A1 (en) 2023-08-03
US10695374B2 (en) 2020-06-30
BR112020014272A2 (pt) 2020-12-15
US20210052652A1 (en) 2021-02-25
US10869893B2 (en) 2020-12-22
US20200261504A1 (en) 2020-08-20
US20230285461A1 (en) 2023-09-14
EA202091754A1 (ru) 2021-02-08
CO2020009869A2 (es) 2020-08-21
MY200985A (en) 2024-01-27
US10888583B2 (en) 2021-01-12
US20200268798A1 (en) 2020-08-27
US11801264B2 (en) 2023-10-31
TW202246307A (zh) 2022-12-01
US20230241112A1 (en) 2023-08-03
US10993962B2 (en) 2021-05-04
US20200085873A1 (en) 2020-03-19
US10888585B2 (en) 2021-01-12
US20210260120A1 (en) 2021-08-26
US10709736B2 (en) 2020-07-14
US11020433B2 (en) 2021-06-01
US11013766B2 (en) 2021-05-25
US10695377B2 (en) 2020-06-30
US11052114B2 (en) 2021-07-06
US10898518B2 (en) 2021-01-26
AU2022202522A1 (en) 2022-05-12
TW202043257A (zh) 2020-12-01
US11058727B2 (en) 2021-07-13
US10874696B2 (en) 2020-12-29
US20210113619A1 (en) 2021-04-22
US20200197441A1 (en) 2020-06-25
US10799537B2 (en) 2020-10-13
EP3755708A1 (en) 2020-12-30
US20210060077A1 (en) 2021-03-04
US20220000922A1 (en) 2022-01-06
US20210052651A1 (en) 2021-02-25
US20210338734A1 (en) 2021-11-04
US20200297771A1 (en) 2020-09-24
BR122020014377A8 (pt) 2023-03-28
US10869894B2 (en) 2020-12-22
US10869890B2 (en) 2020-12-22
CL2020002123A1 (es) 2020-10-16
US10695375B2 (en) 2020-06-30
US20200323909A1 (en) 2020-10-15
US20210060078A1 (en) 2021-03-04
US11013769B2 (en) 2021-05-25
US20200038448A1 (en) 2020-02-06
CA3086916A1 (en) 2019-08-29
AU2019225879B2 (en) 2022-01-27
US11179418B2 (en) 2021-11-23
US10751369B2 (en) 2020-08-25
US20200297770A1 (en) 2020-09-24
US20200038446A1 (en) 2020-02-06
US10905719B2 (en) 2021-02-02
CL2021000842A1 (es) 2021-09-03
US20200206268A1 (en) 2020-07-02
US20210069251A1 (en) 2021-03-11
US10780122B2 (en) 2020-09-22
US10888584B2 (en) 2021-01-12
US20200323914A1 (en) 2020-10-15
US20200268799A1 (en) 2020-08-27
US10898519B2 (en) 2021-01-26
US20200261505A1 (en) 2020-08-20
US20200297772A1 (en) 2020-09-24
US20200222465A1 (en) 2020-07-16
BR122020014377A2 (pt) 2020-12-29
US20230241109A1 (en) 2023-08-03
US10702553B2 (en) 2020-07-07
US11103535B2 (en) 2021-08-31
SG10202010171VA (en) 2020-11-27
US20200093862A1 (en) 2020-03-26
US20200323915A1 (en) 2020-10-15
US20230233612A1 (en) 2023-07-27
US10869895B2 (en) 2020-12-22
US10709738B2 (en) 2020-07-14
US11077142B2 (en) 2021-08-03
US11154576B2 (en) 2021-10-26
US10695373B2 (en) 2020-06-30
AU2022202512A1 (en) 2022-05-12
CR20200365A (es) 2020-09-18
US20210052654A1 (en) 2021-02-25
US20200306305A1 (en) 2020-10-01
EP4321529A3 (en) 2024-07-17
US20200038447A1 (en) 2020-02-06
AU2019225879A1 (en) 2020-07-09
US20200323906A1 (en) 2020-10-15
AU2020204568B2 (en) 2022-02-03
PE20210376A1 (es) 2021-03-02
PE20211300A1 (es) 2021-07-20
MX2020007767A (es) 2020-10-12
US20200323910A1 (en) 2020-10-15
US20200155604A1 (en) 2020-05-21
JP7384884B2 (ja) 2023-11-21
JP2021514178A (ja) 2021-06-10
EP4321529A2 (en) 2024-02-14
US11033583B2 (en) 2021-06-15
US20210213064A1 (en) 2021-07-15
US20200171091A1 (en) 2020-06-04
US20190255112A1 (en) 2019-08-22
JP2025000689A (ja) 2025-01-07
IL276987A (en) 2020-10-29
US20210145888A1 (en) 2021-05-20
US20230241114A1 (en) 2023-08-03
MA51890A (fr) 2020-12-30
US11147839B2 (en) 2021-10-19
US20210052653A1 (en) 2021-02-25
EA202091833A1 (ru) 2020-11-25
US11357797B2 (en) 2022-06-14
TWI837747B (zh) 2024-04-01
US10869892B2 (en) 2020-12-22
US10874695B2 (en) 2020-12-29
US20200323913A1 (en) 2020-10-15
US11065279B2 (en) 2021-07-20
JP7732024B2 (ja) 2025-09-01
US11026977B2 (en) 2021-06-08
US10792307B2 (en) 2020-10-06
US11918607B2 (en) 2024-03-05
SG11202006630RA (en) 2020-09-29
US20200155605A1 (en) 2020-05-21
US20230263830A1 (en) 2023-08-24
US20200163996A1 (en) 2020-05-28
US20210338735A1 (en) 2021-11-04
CL2021000841A1 (es) 2021-09-03
US10888586B2 (en) 2021-01-12
JP7536642B2 (ja) 2024-08-20
US20190255110A1 (en) 2019-08-22
US20200323907A1 (en) 2020-10-15
US20210145887A1 (en) 2021-05-20
US20230285460A1 (en) 2023-09-14
US20200085874A1 (en) 2020-03-19
US20200268800A1 (en) 2020-08-27
AU2022202512B2 (en) 2023-12-14
US20200179454A1 (en) 2020-06-11
JP2024099580A (ja) 2024-07-25
US10780124B2 (en) 2020-09-22
US10772915B2 (en) 2020-09-15
US11033585B2 (en) 2021-06-15
US11147838B2 (en) 2021-10-19
US20210060074A1 (en) 2021-03-04
US10792308B2 (en) 2020-10-06
US11779606B2 (en) 2023-10-10
US20200261506A1 (en) 2020-08-20
MX2020007808A (es) 2020-10-05
US20230285462A1 (en) 2023-09-14
US20200323911A1 (en) 2020-10-15
US20210137986A1 (en) 2021-05-13
US11052113B2 (en) 2021-07-06
KR20200116527A (ko) 2020-10-12
AU2022202520A1 (en) 2022-05-12
US20200179453A1 (en) 2020-06-11
KR20200123134A (ko) 2020-10-28
US10888582B2 (en) 2021-01-12
US10894064B2 (en) 2021-01-19
US20200108097A1 (en) 2020-04-09
US20200323919A1 (en) 2020-10-15
US10869896B2 (en) 2020-12-22
WO2019162110A1 (en) 2019-08-29
US20230241108A1 (en) 2023-08-03
US10869891B2 (en) 2020-12-22
US20200306308A1 (en) 2020-10-01
US20210100845A1 (en) 2021-04-08
US11369636B2 (en) 2022-06-28
US11376281B2 (en) 2022-07-05
US11141437B2 (en) 2021-10-12
JP2022050398A (ja) 2022-03-30
PH12020551295A1 (en) 2021-07-12
US10709737B2 (en) 2020-07-14
TW201936630A (zh) 2019-09-16
US20200323918A1 (en) 2020-10-15
US20230241113A1 (en) 2023-08-03
US20230241110A1 (en) 2023-08-03
US20210145886A1 (en) 2021-05-20
US11197892B2 (en) 2021-12-14
US11020434B2 (en) 2021-06-01
CL2020002387A1 (es) 2021-02-12
US20190255164A1 (en) 2019-08-22
US20210244765A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
US11357797B2 (en) Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
CN112512639A (zh) B*07限制肽和肽组合的抗癌免疫治疗和相关方法
CN112789285A (zh) B*44 限制肽在抗癌免疫治疗的用途和相关方法
CN113164569A (zh) A*01限制肽和肽组合物在抗癌免疫治疗中的用途和相关方法
CN112399853A (zh) A*03限制肽在抗癌免疫治疗和相关方法中的用途
CN113150115A (zh) 用于抗癌免疫治疗的肽
CN113260376A (zh) B*08限制肽和肽组合物抗癌免疫治疗和相关方法
CN112920257A (zh) 用于不同类型癌症免疫治疗的非经典来源的肽和肽组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination